manipulation at its best, page-13

First 13 Last

Share
Profile

Follow
newB

7,135 Posts.

546

06/06/24

17:11

Post #: 74199669
Share

Originally posted by bid: ↑

Here is what they actually said.

I interpret that to mean that it’s not that big pharma are not interested but that atm they are generally concentrating efforts on their own internal developments. That could change if SPL were to initiate further development themselves. Which I suspect really means that at the moment the DEP is no risk to Pfizer and irinotecan, Sanofi and cabazitaxel. But if we did manage to secure a partner to help develop, then you could bet they would want it then! At ASCO they will target and deliberately expose us to these other companies more likely to partner at this stage than the ones that own the existing drugs. I think they are trying everything they can. You’re always down in the dumps, there’s always this tone that you think or want or hope they will fail. I’m a lot more optimistic moving forward and suspect that something will come from ASCO this time round, particularly now that the platform has just been proven and that the latest results from clinical trial are very good imo. I suspect big pharma are playing hard ball with us. Why would they plough money in to develop dep when their own drugs are already established and bring in massive dollars. Out of some sense of a social conscience to provide better outcomes for patients lol doubt that. They know we are no competition and cannot afford to take into phase three ourselves. That’s been the true driver for us to look elsewhere now. ASCO will deliver imo.

Expand

Bid this is one of the most valuable point in this forum.
I am sick of AB's endless, empty ramping.

SPL Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

OJC

SPC to merge with Original Juice Co and Nature One Dairy

There are more pages in this discussion • 54 more messages in this thread...

First 13 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $41.73M

Open	High	Low	Value	Volume
10.0¢	10.0¢	9.8¢	$6.156K	62.05K

Buyers (Bids)

No.	Vol.	Price($)
1	22787	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	199768	2

View Market Depth

No.	Vol.	Price($)
1	22787	0.100
1	97885	0.098
1	64565	0.097
1	50000	0.096
2	60526	0.095

Price($)	Vol.	No.
0.105	199768	2
0.110	226808	10
0.115	85453	2
0.120	79405	9
0.125	70120	2

Last trade - 16.10pm 02/10/2024 (20 minute delay)

SPL (ASX) Chart

manipulation at its best, page-13

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

manipulation at its best, page-13

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SPC to merge with Original Juice Co and Nature One Dairy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News